The Popular Story
  • About Us
  • Articles
  • Success Stories
  • Contact Us
  • About UsArticlesSuccess StoriesContact Us
HomeTop NewsEntertainmentSportsLifestyleAstrologyWorld
Magazine
All IssuesIconic Personalities of the Year 2026July 2026 | The Business Visionaries EditionThe Popular Story 40 Under 40Top 50 Iconic Personalities of 2026
Lists
40 Under 40Top 50 Iconic PersonalitiesIconic Personalities of the Year
Connect+
InstagramFacebookXYouTubeLinkedIn
All Categories
HomeTop NewsEntertainmentSportsLifestyleAstrologyWorldMagazine40 Under 40Top 50 Iconic PersonalitiesIconic Personalities of the YearAbout Us
Font ResizerAa
The Popular StoryThe Popular Story
Search
Follow US
Copyright © 2025-2026 MP Media. All rights reserved.
The Popular Story > Success Stories > Dilip Shanghvi and Sun Pharma: From Five Psychiatry Drugs to India’s Largest Drug Maker
Success StoriesTop News

Dilip Shanghvi and Sun Pharma: From Five Psychiatry Drugs to India’s Largest Drug Maker

By Vinaykant Patel Last updated: November 18, 2026 7 Min Read
Share
GIDC industrial estate in Vapi, Gujarat, where Sun Pharma set up its first plant in 1983

Featured image: Raman Patel, via Wikimedia Commons (CC BY 3.0)

Sun Pharmaceutical Industries reported its September quarter results on 2 November 2026. Consolidated revenue rose 11.8% year on year to Rs 16,100 crore, and adjusted net profit came in at Rs 3,162 crore. Sales in India grew 17.3% to Rs 5,552 crore, and the company’s share of the Indian drug market rose to 8.6%, according to Pharmarack data quoted with the results. Innovative medicines, the patented specialty drugs Sun has spent a decade building, brought in $356 million in the quarter.

Contents
The early yearsThe ideaThe hard partHow it grewWhere it stands nowLessons for founders

Those are big numbers for a company that started in 1983 with five psychiatry products and a two-person marketing team. The man behind it, Dilip Shanghvi, is now Executive Chairman. This is how he got here.

The early years

Shanghvi was born on 1 October 1955 in Amreli, Gujarat, and grew up in Kolkata, where his family moved. His father ran a small wholesale business trading generic medicines. Shanghvi studied commerce at the University of Calcutta and worked in the family trade.

That work taught him how medicines actually moved from maker to chemist, and what doctors asked for. According to a 2019 Business Today review of Soma Das’s biography of him, the family shop was the sole Calcutta stockist for Torrent, then the only Indian drug company focused on psychiatry.

The idea

In the late 1970s Shanghvi decided he would rather make medicines than sell other people’s. He started with one psychiatric drug sourced from a local manufacturer and slowly added more in the same specialty. With few Indian companies focused on psychiatry at the time, it was a field where a newcomer could get known.

Sun Pharmaceutical Industries was set up in 1983 with a small loan from his father. The company’s own milestones page says it began with five psychiatry products, a two-person marketing team and a tablet and capsule plant in Vapi, Gujarat. Its first cardiology products, Monotrate and Angize, followed in 1988, and it opened its first research centre in 1991.

The hard part

Shanghvi’s growth plan rested on buying companies that others did not want. Business Today notes that Sun’s three biggest deals, Caraco in the US, Taro in Israel and Ranbaxy in India, were all distressed assets when Sun took them over. Fixing such businesses takes years and ties up cash and management attention.

Ranbaxy was the biggest test. Sun agreed to buy its domestic rival in 2014 in a deal the company puts at about $4 billion. India’s Competition Commission cleared it only after Sun agreed to sell off seven products. The merger made Sun India’s largest drug maker and, by sales, one of the world’s biggest specialty generic companies.

How it grew

Sun listed on the stock market in 1994. In 1997 it made its first overseas purchase, Caraco Pharmaceutical Laboratories in Detroit. It took a controlling stake in Taro in 2010 and bought out the remaining shares in 2024.

The specialty bet started paying off later. In 2014 Sun licensed tildrakizumab from Merck & Co, and the drug launched in the US as Ilumya in 2018 for plaque psoriasis. Odomzo, Cequa and Winlevi followed. In March 2025 Sun bought Checkpoint Therapeutics, a US cancer drug company, for $355 million, and it launched Leqselvi for severe alopecia areata in the US the same year.

In April 2026 came its largest deal yet: an all-cash agreement to buy US drug maker Organon, the women’s health and biosimilars company spun off from Merck in 2021. Reports put the enterprise value at $11.75 billion. Organon shareholders approved the merger in July 2026, and Sun has said it hopes to close the transaction by early 2027, subject to regulatory approvals.

Where it stands now

Sun sells in more than 100 countries and makes medicines at over 40 sites. In September 2025 Kirti Ganorkar, a chemical engineer who joined Sun in 1996 and had run the India business since 2019, took over as Managing Director. Shanghvi stayed on as Executive Chairman to focus on the specialty portfolio and long-term strategy. Announcing the change in June 2025, he said Ganorkar “has consistently demonstrated effective leadership, managing diverse roles at Sun.”

For the first half of FY27, Sun reported sales of Rs 31,284 crore, with innovative medicines making up 21.5% of the total. R&D spending for the half was Rs 1,605 crore, about 5.1% of sales.

Lessons for founders

  • Start narrow. Five psychiatry drugs gave a small company a field where it could be known by name.
  • Know the trade from the inside. Years in distribution showed Shanghvi what doctors and chemists wanted before he made a single tablet.
  • Buy what you can fix. Troubled assets came cheaper, but only because Sun was willing to do the slow work of repairing them.
  • Change the model before you have to. The move into specialty drugs began long before it showed up in the numbers.
  • Build the next leader from within. Sun’s new MD has spent nearly three decades at the company.

Reporting based on Indian Pharma Post, Sun Pharma milestones, Outlook Business (leadership change), Outlook Business (Organon deal), Business Today and Wikipedia.

Featured image: Raman Patel, via Wikimedia Commons (CC BY 3.0)

Subscribe to Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

[mc4wp_form]

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
[mc4wp_form]
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Email Copy Link Print
By Vinaykant Patel
Vinaykant Patel is an engineer by profession who has developed a strong association with journalism over the past five years. Combining his technical background with an interest in news and public affairs, he brings a distinct perspective to his journalistic work. His journey reflects his commitment to reporting, communication and sharing meaningful stories.
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE NOW

Subscribe to our newsletter to get our newest articles instantly!

[mc4wp_form]

HOT NEWS

Arsenal Face OL Lyonnes on Women’s Champions League Matchday Five

Arsenal and OL Lyonnes are among the teams playing on Thursday, 19 November 2026, in…

November 19, 2026

IFFI’s Films About Films Section Turns the Camera on Cinema Itself

The International Film Festival of India has added a section devoted to films about the…

November 19, 2026

Carlos Alcaraz Reaches ATP Finals Semifinals After Beating Daniil Medvedev

Carlos Alcaraz defeated Daniil Medvedev 6–2, 6–4 at the Nitto ATP Finals on Wednesday, 18…

November 19, 2026

YOU MAY ALSO LIKE

IFFI’s Films About Films Section Turns the Camera on Cinema Itself

The International Film Festival of India has added a section devoted to films about the work and history of making…

Top News
November 19, 2026

Arsenal Face OL Lyonnes on Women’s Champions League Matchday Five

Arsenal and OL Lyonnes are among the teams playing on Thursday, 19 November 2026, in the fifth round of the…

Top News
November 19, 2026

Carlos Alcaraz Reaches ATP Finals Semifinals After Beating Daniil Medvedev

Carlos Alcaraz defeated Daniil Medvedev 6–2, 6–4 at the Nitto ATP Finals on Wednesday, 18 November 2026, and later secured…

Top News
November 19, 2026

Waxing and Waning Moon Explained for Calendar Readers

When a calendar says the Moon is waxing, it means the illuminated portion visible from Earth is growing over successive…

Top News
November 18, 2026
Copyright © 2025-2026 MP Media. All rights reserved.

About Us

The Popular Story is a digital magazine and news publication bringing you stories from entertainment, sports, lifestyle, astrology and the world, with a focus on clear, original and reliable reporting.

Quick Links

  • About The Popular Story
  • Privacy Policy
  • Terms and Conditions
  • Disclaimer
  • Editorial Policy
  • Corrections Policy
  • Our Team

Follow us on Social Media

Explore

  • Contact Us
  • Entertainment
  • Sports
  • Lifestyle

Latest Magazine

View Magazine
© 2026 The Popular Story. All rights reserved.Privacy
Welcome Back!

Sign in to your account

Lost your password?